Objective: The aim of this study was to systematically review the incidence and risk factors for 30 day re-admission to hospital following an index admission to treat diabetes related foot disease (DFD).
Data Sources: A literature search was conducted using Medline/PubMed, Scopus, Cochrane Library, and CINAHL databases.
Methods: The study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Studies that reported the rate of total or DFD related 30 day re-admissions were included. Meta-analysis was performed using a random effects model to calculate the pooled mean (95% confidence interval [CI]) of the proportion of patients re-admitted to hospital within 30 days. Meta-regression was performed to determine the association between risk factors and 30 day re-admission.
Results: Sixteen retrospective studies with a total of 124 683 participants were included. The mean total 30 day re-admission rate was 22.0% (95% CI 17.0 - 27.0%) while the mean DFD related 30 day re-admission rate was 10.0% (95% CI 7.0 - 15.0%). Meta-regression found that greater prevalence of peripheral neuropathy (p = .045) was associated with a higher rate of any 30 day re-admission, and male sex (p = .023) and private health insurance (p = .048) were associated with lower rates of any 30 day re-admission. Coronary artery disease (p= .025) was associated with a higher rate of DFD related re-admission. All studies had low or moderate risk of bias.
Conclusion: This systematic review suggested that about one fifth of patients with DFD are re-admitted to hospital within 30 days, of which about half are to treat DFD. Risk factors for re-admission included female gender, peripheral neuropathy, lack of private health insurance, and coronary artery disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejvs.2023.05.007 | DOI Listing |
Cleft Palate Craniofac J
December 2024
Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY, USA.
Main Objective: To analyze postoperative palatoplasty outcomes before and after systemic protocol changes to preferred bottle and arm immobilizer use after surgery.
Design: Retrospective, cohort study.
Setting: Urban, academic, tertiary medical center in New York City, NY.
J Thorac Dis
November 2024
Faculty of Medical Management, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam.
Background: Postoperative complications and extended length of stays (LOS) following lobectomy for non-small cell lung cancer (NSCLC) remain significant healthcare and economic burdens, especially in developing countries with limited resources. This study evaluated the effectiveness of enhanced recovery after surgery (ERAS) protocols in addressing these issues.
Methods: This observational study compared two groups of patients, utilizing a prospective arm for ERAS and a retrospective arm for routine care.
J Frailty Sarcopenia Falls
December 2024
Department of Geriatric Medicine, Changi General Hospital, Singapore.
Plast Surg (Oakv)
January 2024
Section of Plastic and Reconstructive Surgery, Department of Surgery, University of Calgary Cumming School of Medicine, Calgary, Canada.
Within a resource-limited healthcare system, an emphasis on financial accountability is imperative. Over the past decade at our institution, there have been many operational changes employed to improve patient care during oncologic head and neck resections with free flap (HNFF) reconstruction. The objective of this study is to assess whether these changes are associated with cost savings.
View Article and Find Full Text PDFGynecol Oncol Rep
December 2024
Department of Gynaecology and Gynaecological Oncology, Norfolk and Norwich University Hospital, Norwich NR4 7UY, UK.
Objective: The aim of this study is to evaluate the implementation of the elements of enhanced recovery (ERAS) protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for metastatic ovarian cancer. ERAS protocols have shown improvement in the perioperative outcomes of patients who underwent cytoreductive surgery for metastatic ovarian cancer by reducing the length of stay as well as the postoperative complications and by improving patients' postoperative experience
Methods: This is a feasibility study involving retrospective analysis from (31) patients who underwent cytoreductive surgery and HIPEC versus (35) a control group that underwent cytoreductive surgery only, prior to the introduction of the HIPEC programme for metastatic ovarian cancer. All patients had undergone neoadjuvant chemotherapy prior to surgery.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!